Patient Preferences in the Treatment of Neovascular Age-Related Macular Degeneration

Roodhooft, 2002, Leading causes of blindness worldwide, Bull Soc Belge Ophtalmol, 283, 19 Fong, 2013, Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema, Clin Interv Aging, 8, 467 Martin, 2011, Ranibizumab and bevacizumab for neovascular age-related macular degeneration, N Engl J Med, 364, 1897, 10.1056/NEJMoa1102673 Stellungnahme von Ziemssen, 2015, [Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany], Ophthalmologe, 112, 246, 10.1007/s00347-014-3217-7 Ehlken, 2014, Pons-Studie: Hinweise auf nicht optimale Versorgung der IVOM-Patienten bei neovaskulärer AMD im klinischen Alltag, Der Ophthalmologe, 29 Holz, 2015, Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration, Br J Ophthalmol, 99, 220, 10.1136/bjophthalmol-2014-305327 Cohen, 2013, Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study, Retina, 33, 474, 10.1097/IAE.0b013e31827b6324 Droege, 2014, Patient preference of ranibizumab treatment regimen for neovascular age-related macular degeneration - monthly injections versus pro re nata, Graefes Arch Clin Exp Ophthalmol, 252, 31, 10.1007/s00417-013-2412-6 Horne, 1999, Patients’ beliefs about treatment: the hidden determinant of treatment outcome?, J Psychosom Res, 47, 491, 10.1016/S0022-3999(99)00058-6 Wilke, 2011, Toward identifying the causes and combinations of causes increasing the risks of nonadherence to medical regimens: combined results of two German self-report surveys, Value Health, 14, 1092, 10.1016/j.jval.2011.06.002 Reed Johnson, 2013, Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force, Value Health, 16, 3, 10.1016/j.jval.2012.08.2223 Zhu, 2008 Clark, 2014, Discrete choice experiments in health economics: a review of the literature, Pharmacoeconomics, 32, 883, 10.1007/s40273-014-0170-x Ryan, 1997, Using conjoint analysis to assess women’s preferences for miscarriage management, Health Econ, 6, 261, 10.1002/(SICI)1099-1050(199705)6:3<261::AID-HEC262>3.0.CO;2-N Ryan, 2003, Using discrete choice experiments to value health care programmes: current practice and future research reflections, Appl Health Econ Health Policy, 2, 55 Pfarr, 2014, Using discrete choice experiments to understand preferences in health care, Dev Health Econ Public Policy, 12, 27, 10.1007/978-88-470-5480-6_2 Wolf, 2014, Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research, Graefes Arch Clin Exp Ophthalmol, 252, 647, 10.1007/s00417-013-2562-6 Zwerina McFadden, 1974, Conditional logit analysis of qualitative choice behaviour, 105 Wykoff, 2015, Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results, Ophthalmology, 122, 2514, 10.1016/j.ophtha.2015.08.009